162 related articles for article (PubMed ID: 18758308)
21. Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
Sekine I; Harada H; Yamamoto N; Wakabayashi M; Murakami H; Goto K; Nogami N; Seto T; Oshita F; Okamoto H; Tanaka H; Tamura T; Ishikura S; Ohe Y
Lung Cancer; 2017 Jun; 108():232-237. PubMed ID: 28625642
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
Lopez-Chavez A; Young T; Fages S; Leon L; Schiller JH; Dowlati A; Brahmer JR; Johnson DH; Sandler A
J Thorac Oncol; 2012 Nov; 7(11):1707-12. PubMed ID: 23059774
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
Han JY; Lee DH; Lee SY; Park CG; Kim HY; Lee HG; Lee JJ; Kim HT; Lee JS
Cancer; 2005 Dec; 104(12):2759-65. PubMed ID: 16294344
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Lee JE; Park HS; Jung SS; Kim JO; Kim SY
Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
26. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
[TBL] [Abstract][Full Text] [Related]
28. Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer.
Wahba HA; Halim AA; El-Hadaad HA
Med Oncol; 2012 Mar; 29(1):199-204. PubMed ID: 21140241
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.
Horn L; Zhao Z; Sandler A; Johnson D; Shyr Y; Wolff S; Devore RF; Laskin J
Clin Lung Cancer; 2011 May; 12(3):161-5. PubMed ID: 21663858
[TBL] [Abstract][Full Text] [Related]
30. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.
Fukuda M; Soda H; Fukuda M; Kinoshita A; Nakamura Y; Nagashima S; Takatani H; Tsukamoto K; Kohno S; Oka M
Cancer; 2007 Aug; 110(3):606-13. PubMed ID: 17577234
[TBL] [Abstract][Full Text] [Related]
31. Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.
Hong YS; Lee HR; Park S; Lee SC; Hwang IG; Park BB; Lee J; Ahn JS; Ahn MJ; Lim HY; Park K
Br J Cancer; 2006 Dec; 95(12):1648-52. PubMed ID: 17133266
[TBL] [Abstract][Full Text] [Related]
32. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
33. Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
Kim DW; Kim HG; Kim JH; Park K; Kim HK; Jang JS; Kim BS; Kang JH; Lee KH; Kim SW; Ryoo HM; Kim JS; Lee KH; Kwon JH; Choi JH; Shin SW; Hahn S; Heo DS
Cancer Res Treat; 2019 Jan; 51(1):119-127. PubMed ID: 29529858
[TBL] [Abstract][Full Text] [Related]
34. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Owonikoko TK; Aisner J; Wang XV; Dahlberg SE; Rubin EH; Ramalingam SS; Gounder M; Rausch PG; Axelrod RS; Schiller JH
Cancer Chemother Pharmacol; 2014 Jan; 73(1):171-80. PubMed ID: 24288121
[TBL] [Abstract][Full Text] [Related]
35. A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.
Han JY; Nam BH; Kim HY; Yoon SJ; Kim HT; Lee JS
Ann Oncol; 2012 Nov; 23(11):2925-2930. PubMed ID: 22782331
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
37. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.
Lara PN; Chansky K; Shibata T; Fukuda H; Tamura T; Crowley J; Redman MW; Natale R; Saijo N; Gandara DR
Cancer; 2010 Dec; 116(24):5710-5. PubMed ID: 20737417
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.
Sorensen M; Lassen U; Jensen PB; Østerlind K; Jeppesen N; Jensen BB; Mellemgaard A; Rytter C; Langer SW
J Thorac Oncol; 2008 Aug; 3(8):902-6. PubMed ID: 18670309
[TBL] [Abstract][Full Text] [Related]
39. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design.
Kleinberg LR; Catalano PJ; Forastiere AA; Keller SM; Mitchel EP; Anne PR; Benson AB
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):738-46. PubMed ID: 26972646
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
Bae SH; Ryoo HM; Do YR; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Lee WS; Hur IK; Baek JH; Park KU
Lung Cancer; 2008 Jan; 59(1):76-80. PubMed ID: 17767977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
